Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pfizer Inc's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook.
Madison, New Jersey-based Zoetis, which priced 86.1 million shares at $26 according to an underwriter, is now valued at around $13 billion. Shares of the company, which sells an array of products for livestock and domestic pets, were expected to price in a range of $22 to $25.
…The deal was between 10 and 20 times oversubscribed, according to a source with direct knowledge, meaning demand for the deal was very high [no kidding].
Zoetis, with annual sales of about $4.2 billion and 9,000 employees worldwide, is the largest player in the $22 billion animal health industry. It sells vaccines, diagnostics, anti-infectives and other medicines.
About two thirds of its sales are from products and services for livestock, including dairy and beef cattle, pigs, poultry and sheep. [Products for cattle comprise 38% of total revenues, according to the roadshow materials.] Its pet products include Revolution, a heartworm and flea-control medicine for cats and dogs, and Palladia, a cancer drug for dogs. The business began in 1952 as the Agriculture Division of Pfizer, and has steadily grown through in-house research and almost a dozen acquisitions, including the animal health units of rival drugmakers.
…Zoetis has operations in 60 countries, including emerging markets in Asia and South America.[61% of sales were ex-US in 2011 (the most recent full year for which data are available)].
Zoetis (zo-ET-is) is the animal-health business formerly owned by Pfizer that is now fullly independent. It is the largest animal-health company in the world with annual sales of >$4B.